Evaluation of the usefulness of letrozole as hormone therapy for postmenopausal patients with Ductal Carcinoma In Situ (DCIS)
Phase 2
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000000966
- Lead Sponsor
- St. Luke's International Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Female
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Patients receiving drugs having a potential influence on the status of sex hormones (hormone replacement therapy, raloxifene, etc.). (However, patients after washout for at least 2 months can be enrolled.) (2)Patients with bilateral DCIS. (3)Patients within 30 days after completion of treatment with the investigational drugs.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Objective response
- Secondary Outcome Measures
Name Time Method Clinical usefulness Safety